- Conditions
- Childhood Idiopathic Nephrotic Syndrome
- Interventions
- Obinutuzumab, MMF, Prednisone, Methylprednisolone, Acetaminophen/ Paracetamol, Diphenhydramine Hydrochloride
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Miami, Florida • Orlando, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 1,319
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
- Interventions
- IAM1363
- Drug
- Lead sponsor
- Iambic Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 23 more
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
- Interventions
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Biological · Drug
- Lead sponsor
- Rapa Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Multiple Myeloma
- Interventions
- JCARH125, JCARH125 + anakinra
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
- Conditions
- HIV, AIDS
- Interventions
- individualized Texting for Adherence Building (iTAB), Psychoeducation
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Autism Spectrum Disorder, Autistic Disorder, Autism, Asperger's Syndrome, Pervasive Development Disorders
- Interventions
- Folinic Acid and placebo, Folinic Acid
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 3 Years to 14 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- High-risk Muscle Invasive Urothelial Carcinoma
- Interventions
- Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 19
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
- Conditions
- Smoking
- Interventions
- Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03 mg), Behavioral Activation, Supportive Counseling
- Drug · Behavioral
- Lead sponsor
- Maggie M Sweitzer, PhD
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
- Interventions
- Bridging radiotherapy (BRT), Conditioning chemotherapy, CAR T-cell product
- Radiation · Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 61 more
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Interventions
- TT-816, A PD-1 inhibitor
- Drug
- Lead sponsor
- Teon Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Nashville, Tennessee • Austin, Texas • San Antonio, Texas + 2 more
- Conditions
- Type2 Diabetes
- Interventions
- Afrezza Inhalant Product
- Drug
- Lead sponsor
- Model Clinical Research LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Paroxysmal Atrial Fibrillation
- Interventions
- Synaptic Cryoablation System
- Device
- Lead sponsor
- Synaptic Medical Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Jonesboro, Arkansas • Los Angeles, California + 6 more
- Conditions
- Leukemia, Myelogenous, Acute
- Interventions
- Natural Killer Cells, Fludarabine, Cyclophosphamide, Denileukin diftitox, Donor lymphapheresis, IL-2
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Substance Use Disorders
- Interventions
- Standard Contingency Management (CM), Enhanced Contingency Management (CM+)
- Behavioral
- Lead sponsor
- Oregon Social Learning Center
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- HIV, Adolescent Behavior, Gender
- Interventions
- Male-Specific Intervention Package, Female-Specific Intervention Package, Pre-Exposure Prophylaxis (Females), Cash Transfer Cohort (Females)
- Other · Drug · Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 1,215 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
- Interventions
- acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 13
- States / cities
- Campbell, California • Duarte, California • Long Beach, California + 9 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab emtansine
- Drug
- Lead sponsor
- Jenny C. Chang, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Schizophrenia
- Interventions
- Dextroamphetamine, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Prostate Cancer
- Interventions
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Drug
- Lead sponsor
- Carolina Research Professionals, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
- Interventions
- Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Alzheimer's Disease
- Interventions
- Carvedilol, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Up to 100 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer, Colorectal Cancer
- Interventions
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Denver, Colorado • Sarasota, Florida + 6 more
- Conditions
- Substance Abuse
- Interventions
- Strengthening Families Program Online eLearning Game, SFP Home-use DVD, Wait-Listed Control
- Behavioral
- Lead sponsor
- Strengthening Families Program LLC
- Industry
- Eligibility
- 11 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah